ATC codes:
L04AB04
EMLc
Indication
Juvenile idiopathic arthritis
ICD11 code:
FA24.Z
INN
Adalimumab
Medicine type
Biological agent
List type
Complementary
(EML)
(EMLc)
(EMLc)
Additional notes
EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars. EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.
Formulations
Parenteral > General injections > SC:
40 mg per 0.8 mL ;
40 mg per 0.4 mL ;
10 mg per 0.2 mL
(EMLc)
;
20 mg per 0.4 mL
(EMLc)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more
information on specific patents and license status for developing countries visit www.MedsPal.org
Read more
about patents.
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc.
Listing of adalimumab for the indication of juvenile idiopathic arthritis was transferred from Section 8.1 (Immunomodulators for non-malignant disease) to Section 29.3 (Juvenile joint diseases).